Full Text
PT14 Do Breakthrough Therapies Demonstrate Breakthrough Value to Payers? An Evaluation of US Hemophilia B Gene Therapy Access Policies

Abstract

Authors

Lake D. Murphy Betsy J. Lahue

Back to Volume 28, Supplemental Issue 6S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×